Antineo is specialized in preclinical services to test future anticancer agents. We realize proof-of-concept studies in vitro, ex vitro and in vivo (CDX on immunocompromised, humanized mice, or syngeneic). Our expertise allows to optimize the preclinical steps of drug development strategies with the choice of the indication, relevant model, and adequate references/combinations. We also provide a panel of secondary resistance models (chemo and immunotherapies, immune checkpoint inhibitors).
8 avenue Rockefeller 69008 Lyon
Targeted indications : breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, supportive care, liver cancer, brain cancer, head & neck cancer, gastrointestinal cancer, gynecological cancer, bone cancer, genitourinary cancer, skin cancer, hematologic cancer, lymphoma, myeloma, leukemia, predictive toxicology.